These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35950859)

  • 1. Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
    Duan S; Yu X; Wang C; Meng L; Gai Y; Zhou Y; Gu T; Yu B; Wu J; Yu X
    J Virol; 2022 Sep; 96(17):e0055522. PubMed ID: 35950859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
    Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
    J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Vif-Mediated Degradation of APOBEC3G through Competitive Binding of Core-Binding Factor Beta.
    Miyagi E; Welbourn S; Sukegawa S; Fabryova H; Kao S; Strebel K
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase.
    Fribourgh JL; Nguyen HC; Wolfe LS; Dewitt DC; Zhang W; Yu XF; Rhoades E; Xiong Y
    J Virol; 2014 Mar; 88(6):3309-19. PubMed ID: 24390320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.
    Matsui Y; Shindo K; Nagata K; Yoshinaga N; Shirakawa K; Kobayashi M; Takaori-Kondo A
    J Biol Chem; 2016 Nov; 291(48):24892-24899. PubMed ID: 27758855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of Vif-Derived Peptide Inhibitors with Anti-HIV-1 Activity by Interrupting Vif-CBFβ Interaction.
    Gai Y; Duan S; Wang S; Liu K; Yu X; Yang C; Li G; Zhou Y; Yu B; Wu J; Wang C; Yu X
    Viruses; 2024 Mar; 16(4):. PubMed ID: 38675833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s.
    Hu Y; Knecht KM; Shen Q; Xiong Y
    FEBS J; 2021 Jun; 288(11):3407-3417. PubMed ID: 32893454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
    Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
    mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFβ that is critical for Vif function.
    Desimmie BA; Smith JL; Matsuo H; Hu WS; Pathak VK
    Retrovirology; 2017 Mar; 14(1):19. PubMed ID: 28302150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression.
    Zhou X; Han X; Zhao K; Du J; Evans SL; Wang H; Li P; Zheng W; Rui Y; Kang J; Yu XF
    J Virol; 2014 Mar; 88(5):2555-63. PubMed ID: 24352440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
    Pery E; Rajendran KS; Brazier AJ; Gabuzda D
    J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces.
    Hultquist JF; McDougle RM; Anderson BD; Harris RS
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1543-51. PubMed ID: 22725134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components.
    Zhou X; Evans SL; Han X; Liu Y; Yu XF
    PLoS One; 2012; 7(3):e33495. PubMed ID: 22479405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.
    Miyagi E; Kao S; Yedavalli V; Strebel K
    J Virol; 2014 May; 88(9):4839-52. PubMed ID: 24522927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
    Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
    J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
    Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
    J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.